Corrigendum to "Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein" [Vaccine 40(20) (2022) 2856-2868]
Vaccine. 2022 Nov 15;40(48):7009. doi: 10.1016/j.vaccine.2022.10.019. Epub 2022 Oct 28.NO ABSTRACTPMID:36374711 | DOI:10.1016/j.vaccine.2022.10.019 (Source: Vaccine)
Source: Vaccine - November 14, 2022 Category: Allergy & Immunology Authors: Mohammad Hassan Pouriayevali Ali Teimoori Saber Esmaeili Asghar Abdoli Delaram Doroud Mostafa Salehi-Vaziri Maryam Shahali Maryam Kadkhodazadeh Talieh Sabouni Mohammad Ali Khosravi Mohammad Panahi Fereidoon Khoshroo Anahita Bahmanjeh Yury Valdes-Balbin Da Source Type: research

Immunization with a tri-antigen syphilis vaccine significantly attenuates chancre development, reduces bacterial load, and inhibits dissemination of Treponema pallidum
Vaccine. 2022 Nov 11:S0264-410X(22)01372-X. doi: 10.1016/j.vaccine.2022.11.002. Online ahead of print.ABSTRACTSyphilis continues to be a significant public health concern worldwide. The disease is endemic in many low- and middle-income countries, and rates have risen sharply in high-income countries over the last decade. The continued prevalence of infectious and congenital syphilis worldwide highlights the need for the development of an effective syphilis vaccine to complement public health measures for syphilis control. The complex, multi-stage course of syphilis infection necessitates a holistic approach to the developm...
Source: Vaccine - November 14, 2022 Category: Allergy & Immunology Authors: Sheila A Lukehart Barbara Molini Alloysius Gomez Charmie Godornes Rebecca Hof Mark C Fernandez Ragan A Pitner Sean A Gray Darrick Carter Lorenzo Giacani Caroline E Cameron Source Type: research

A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model
In this study, the E5aa28-46, E6aa37-57 and E7aa26-57 peptides were selected and linked to form a novel multi-epitopes vaccine (E765m), which was inserted into the major immune dominant region (MIR) of hepatitis B virus core antigen (HBc) to construct a HBc-E765m chimeric virus-like particles (cVLPs). The immunogenicity and immunotherapeutic effect of the cVLPs vaccine was evaluated in immunized mice and a tumor-bearing mouse model. The results showed that HBc-E765m cVLPs elicited high E5-, E6- and E7- specific CTL and serum IgG antibody responses, and also relatively high levels of the cytokines IFN-γ, IL-4 and IL-5. Mor...
Source: Vaccine - November 14, 2022 Category: Allergy & Immunology Authors: Wang Qi Li Qingfeng Zhang Jing Zheng Maolin Zhang Zhihui Du Wangqi Zhu Shanli Chen Jun Jiang Pengfei Zhang Lifang Source Type: research

Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway
CONCLUSION: We found no evidence of increased short-term mortality among vaccinated individuals in the older population after matching on sociodemographic and clinical characteristics affecting vaccination and mortality.PMID:36376216 | DOI:10.1016/j.vaccine.2022.10.085 (Source: Vaccine)
Source: Vaccine - November 14, 2022 Category: Allergy & Immunology Authors: Paz Lopez-Doriga Ruiz Nina Gunnes Jon Michael Gran Øystein Karlstad Randi Selmer Jesper Dahl H åkon Bøås Richard Aubrey White Aurora Christine Hofman Trine Hessevik Paulsen Sara Viksmoen Watle Anette Hylen Ranhoff Geir Bukholm Hanne L øvdal Gulseth G Source Type: research

Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults
CONCLUSIONS: History of SARS-CoV-2 infection was significantly associated with severe systemic AEs following dose 1 of mRNA COVID-19 vaccine; the effect varied by vaccine received. Most participants who experienced severe systemic AEs following dose 1 did not require medical attention of any kind for symptoms following dose 2. Vaccine providers can use these findings to counsel patients who had pre-vaccination SARS-CoV-2 infection histories, experienced severe systemic AEs following dose 1, and are considering not receiving additional mRNA COVID-19 vaccine doses.PMID:36372665 | DOI:10.1016/j.vaccine.2022.10.073 (Source: Vaccine)
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Lindsay K Tompkins James Baggs Tanya R Myers Julianne M Gee Paige L Marquez Sharon B Kennedy David Peake Dhruv Dua Anne M Hause Penelope Strid Winston Abara Rebecca Rossetti Tom T Shimabukuro David K Shay Source Type: research

Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET
CONCLUSION: Vaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021. Compared to the age-matched general population it was higher in the beginning and similar by the end of the study period. Ethics approval: Trial registration: BASEC 2021-00444, Ethikkommission Zürich (Cantonal Ethics Committee Zurich), Switzerland, registered February 24th 2021.PMID:36372666 | DOI:10.1016/j.vaccine.2022.10.089 (Source: Vaccine)
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Stephan Skawran Helen Schiesser Alexander Maurer Thomas Sartoretti Manuel Dittli C äcilia Mader Alessandra Curioni-Fontecedro Christoph Berger Martin W Huellner Michael Messerli Source Type: research

Letting kids play their CARDs (Comfort, Ask, Relax, Distract) to help cope with needle-related fear and pain: Results from user testing
This study examined perceptions of children and parents about a new web-based CARD (Comfort, Ask, Relax, Distract) game that teaches children how to cope with needle-related pain and fear. A convenience sample of 15 child-parent dyads (children, 6-12 years) participated. Children played the game on a handheld device while being virtually monitored. Activity tracking revealed most children engaged with multiple components. Children reported they understood the game, it was easy to play, they learned coping strategies and believed they could implement them. Children reported lower fear of needles after playing. Parents liked...
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Anna Taddio Anthony N T Ilersich Lucie Bucci C Meghan McMurtry Victoria Gudzak Moshe Ipp Tina Zita Shenthuraan Tharmarajah Noni MacDonald Source Type: research

Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study
This study aimed to investigate COVID-19 vaccine uptake by occupation, including for vulnerable groups and by occupational exposure status.METHODS: We used data from employed or self-employed adults who provided occupational information as part of the Virus Watch prospective cohort study (n = 19,595) and linked this to study-obtained information about vulnerability-relevant characteristics (age, medical conditions, obesity status) and work-related COVID-19 exposure based on the Job Exposure Matrix. Participant vaccination status for the first, second, and third dose of any COVID-19 vaccine was obtained based on linkage to ...
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Sarah Beale Rachel Burns Isobel Braithwaite Thomas Byrne Wing Lam Erica Fong Ellen Fragaszy Cyril Geismar Susan Hoskins Jana Kovar Annalan M D Navaratnam Vincent Nguyen Parth Patel Alexei Yavlinsky Martie Van Tongeren Robert W Aldridge Andrew Hayward Viru Source Type: research

Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study
CONCLUSIONS: The COVID-19 pandemic continues to impose a considerable impact on HCP. The administration of a vaccine dose in less than four months before significantly protected against COVID-19 and absenteeism duration, irrespective of COVID-19 vaccination status. Defining the optimal timing of boosters is imperative.PMID:36372669 | DOI:10.1016/j.vaccine.2022.10.049 (Source: Vaccine)
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Helena C Maltezou Maria N Gamaletsou Dimitra-Maria Koukou Theodoros V Giannouchos Flora Sourri Natalia Syrimi Amalia Karapanou Nikolaos Lemonakis Emmanuela Peskelidou Konstantina Papanastasiou Periklis Panagopoulos Kyriakos Souliotis Athanasia Lourida Dim Source Type: research

Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques
Vaccine. 2022 Nov 8:S0264-410X(22)01379-2. doi: 10.1016/j.vaccine.2022.10.092. Online ahead of print.ABSTRACTSARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4 and BA.5 have been spreading rapidly and become dominant worldwide. Here we report the homologous or heterologous booster effects of S-268019-b, a recombinant spike protein vaccine with the squalene-based adjuvant A-910823 in cynomolgus macaques. In macaques which had been primed with S-268019-b or mRNA vaccines, boosting with S-268019-b enhanced neutralizing antibodies (NAb) against ancestral SARS-CoV-2. Since boosting with the antigen without adjuvant did not ...
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Masayuki Hashimoto Shinpei Aoe Yusuke Kawazu Naomi M Seki Kumi Hashimoto Ken Yoshihara Tomoyuki Homma Takuhiro Sonoyama Shinya Omoto Source Type: research

Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults
CONCLUSIONS: History of SARS-CoV-2 infection was significantly associated with severe systemic AEs following dose 1 of mRNA COVID-19 vaccine; the effect varied by vaccine received. Most participants who experienced severe systemic AEs following dose 1 did not require medical attention of any kind for symptoms following dose 2. Vaccine providers can use these findings to counsel patients who had pre-vaccination SARS-CoV-2 infection histories, experienced severe systemic AEs following dose 1, and are considering not receiving additional mRNA COVID-19 vaccine doses.PMID:36372665 | DOI:10.1016/j.vaccine.2022.10.073 (Source: Vaccine)
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Lindsay K Tompkins James Baggs Tanya R Myers Julianne M Gee Paige L Marquez Sharon B Kennedy David Peake Dhruv Dua Anne M Hause Penelope Strid Winston Abara Rebecca Rossetti Tom T Shimabukuro David K Shay Source Type: research

Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET
CONCLUSION: Vaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021. Compared to the age-matched general population it was higher in the beginning and similar by the end of the study period. Ethics approval: Trial registration: BASEC 2021-00444, Ethikkommission Zürich (Cantonal Ethics Committee Zurich), Switzerland, registered February 24th 2021.PMID:36372666 | DOI:10.1016/j.vaccine.2022.10.089 (Source: Vaccine)
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Stephan Skawran Helen Schiesser Alexander Maurer Thomas Sartoretti Manuel Dittli C äcilia Mader Alessandra Curioni-Fontecedro Christoph Berger Martin W Huellner Michael Messerli Source Type: research

Letting kids play their CARDs (Comfort, Ask, Relax, Distract) to help cope with needle-related fear and pain: Results from user testing
This study examined perceptions of children and parents about a new web-based CARD (Comfort, Ask, Relax, Distract) game that teaches children how to cope with needle-related pain and fear. A convenience sample of 15 child-parent dyads (children, 6-12 years) participated. Children played the game on a handheld device while being virtually monitored. Activity tracking revealed most children engaged with multiple components. Children reported they understood the game, it was easy to play, they learned coping strategies and believed they could implement them. Children reported lower fear of needles after playing. Parents liked...
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Anna Taddio Anthony N T Ilersich Lucie Bucci C Meghan McMurtry Victoria Gudzak Moshe Ipp Tina Zita Shenthuraan Tharmarajah Noni MacDonald Source Type: research

Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study
This study aimed to investigate COVID-19 vaccine uptake by occupation, including for vulnerable groups and by occupational exposure status.METHODS: We used data from employed or self-employed adults who provided occupational information as part of the Virus Watch prospective cohort study (n = 19,595) and linked this to study-obtained information about vulnerability-relevant characteristics (age, medical conditions, obesity status) and work-related COVID-19 exposure based on the Job Exposure Matrix. Participant vaccination status for the first, second, and third dose of any COVID-19 vaccine was obtained based on linkage to ...
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Sarah Beale Rachel Burns Isobel Braithwaite Thomas Byrne Wing Lam Erica Fong Ellen Fragaszy Cyril Geismar Susan Hoskins Jana Kovar Annalan M D Navaratnam Vincent Nguyen Parth Patel Alexei Yavlinsky Martie Van Tongeren Robert W Aldridge Andrew Hayward Viru Source Type: research

Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study
CONCLUSIONS: The COVID-19 pandemic continues to impose a considerable impact on HCP. The administration of a vaccine dose in less than four months before significantly protected against COVID-19 and absenteeism duration, irrespective of COVID-19 vaccination status. Defining the optimal timing of boosters is imperative.PMID:36372669 | DOI:10.1016/j.vaccine.2022.10.049 (Source: Vaccine)
Source: Vaccine - November 13, 2022 Category: Allergy & Immunology Authors: Helena C Maltezou Maria N Gamaletsou Dimitra-Maria Koukou Theodoros V Giannouchos Flora Sourri Natalia Syrimi Amalia Karapanou Nikolaos Lemonakis Emmanuela Peskelidou Konstantina Papanastasiou Periklis Panagopoulos Kyriakos Souliotis Athanasia Lourida Dim Source Type: research